Serum sodium predicts mortality in patients listed for liver transplantation

Hepatology

Volumn 41, Issue 1, 2005, Pages 32-39

  Biggins, Scott W ^a   Rodriguez, Harry J ^a   Bacchetti, Peter ^b   Bass, Nathan M ^a   Roberts, John P ^a   Terrault, Norah A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SODIUM;

ADULT; AGED; ARTICLE; ASCITES; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MODEL; MORTALITY; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; SODIUM BLOOD LEVEL;

ADULT; AGED; COHORT STUDIES; DECISION SUPPORT TECHNIQUES; FEMALE; HEALTH CARE RATIONING; HUMANS; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; SODIUM; WAITING LISTS;

EID: 11244299379     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20517     Document Type: Article

References (26)

1. Freeman RB Jr, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002;8:851-858.
2. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649.
3. Botero RC, Lucey MR. Organ allocation: model for end-stage liver disease, Child-Turcotte-Pugh, Mayo risk score, or something else. Clin Liver Dis 2003;7:715-727.
4. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. HEPATOLOGY 2000;31:864-871.
5. Kamath P, Wiesner R, Malinchoc M, Kremers W, Therneau T, Kosberg C. A model to predict survival in patients with end-stage liver disease. HEPATOLOGY 2001;33:464-470.
6. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-96.
7. Heuman DM, Mihas A. Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer. Gastroenterology 2003;125:992-993.
8. Potcel A, Diaz F, Rendon P, Macias M, Martin-Hertera L, Giron-Gonzalez JA. Dilutional hyponatremia in patients with cirrhosis and ascites. Arch Intern Med 2002;162:323-328.
9. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003;38(Suppl 1):S69-S89.
10. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-236.
11. Cosby RL, Yee B, Schrier RW. New classification with prognostic value in cirrhotic patients. Miner Electrolyte Metab 1989;15:261-266.
12. Borroni G, Maggi A, Sangiovanni A, Cazzaniga M, Salerno F. Clinical relevance of hyponatraemia for the hospital outcome of cirthotic patients. Dig Liver Dis 2000;32:605-610.
13. Fernandez-Espartach G, Sanchez-Fueyo A, Gines P, Uriz J, Quinto L, Ventura PJ, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001;34:46-52.
14. Sheat L, Kleinerman J, Gabuzda GJ. Renal failure in patients with cirrhosis of the liver. I. Clinical and pathologic charactetistics. Am J Med 1965;39:184-198.
15. Llach J, Gines P, Arroyo V, Rimola A, Tito L, Badalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988;94:482-487.
16. Earley L, Sanders C. The effect of changing serum osmolality on the release of antidiuretic hormone in certain patients with decompensated cirrhosis of the liver and low osmolality. J Clin Invest 1959;38:545-550.
17. Arroyo V, Rodes J, Gutierrez-Lizarraga MA, Revert L. Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis 1976;21:249-256.
18. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a non-parametric approach. Biometrics 1988;44:837-845.
19. Schrier RW, Gurevich AK, Cadnapaphornchai MA. Pathogenesis and management of sodium and water retention in cardiac failure and cirrhosis. Semin Nephrol 2001;21:157-172.
20. Bosch J, Arroyo V, Betriu A, Mas A, Carrilho F, Rivera F, et al. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirthosis. Gastroenterology 1980;78:92-99.
21. Albillos A, Colombato LA, Groszmann RJ. Vasodilatation and sodium tetention in prehepatic portal hypertension. Gastroenterology 1992;102:931-935.
22. La Villa G, Salmeron JM, Arroyo V, Bosch J, Gines P, Garcia-Pagan JC, et al. Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension. Gastroenterology 1992;102:2114-2119.
23. Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis L. Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med 1995;122:816-822.
24. Gerbes AL, Gülberg V, Ginès P, Decaux G, Gross P, Gandjini H, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003;124:933-939.
25. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. HEPATOLOGY 2003;37:182-191.
26. Runyon BA. Management of adult patients with ascites due to cirrhosis. HEPATOLOGY 2004;39:841-856.